has denied patients access to a 'pioneering', 'breakthrough', 'revolutionary' treatment. While this particular type of lymphoma doesn't have a standard therapy, yet, most . Sativex is a cannabis extract which contains both THC and CBD. New cancer drug appears to cure a third of terminal lymphoma patients the NHS has worked to make this pioneering treatment available so. CBD oil tumors. No pet owner ever wants to hear their dog has lymphoma–But . CBD & Lymphoma – Pioneering Breakthrough Therapies.
Lymphoma – Therapies CBD & Pioneering Breakthrough
Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of CBD medicines for a range of important unmet medical needs, with an initial focus on GVHD and treatment of acute and chronic pain.
This press release may contain certain forward-looking information and statements "forward-looking information" within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation in respect of its product candidate pipeline, planned clinical trials, regulatory approval prospects, intellectual property objectives and other statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions.
Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the ris k that future clinical studies may not proceed as expected or may produce unfavourable results. Kalytera undertakes no obligation to comment on analyses, expectations or statements made by third parties, its securities, or financial or operating results as applicable.
Although Kalytera believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Kalytera's control. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof.
Kalytera disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. Search Now you can search stock related news and private companies such as Airbnb. No matching results for ''. Try a valid symbol or a specific company name for relevant results.
Give feedback on the new search experience. In the second of the two prior Phase 2a clinical studies, 12 patients were administered CBD at a dose of mg administered twice daily from 7 days prior to the bone marrow transplant procedure until up to days post transplantation. Based on the positive and encouraging results from the two prior Phase 2a clinical studies that we completed in prevention of GVHD, we are optimistic that our CBD product will address this unmet need, and will be demonstrated to be a safe and effective means to prevent the onset of acute GVHD.
We are planning to initiate a seamless Phase pivotal registration study in the treatment of acute GVHD later this year. There are currently few options to treat patients with acute GVHD, a critically underserved market. Our Phase pivotal registration study will enroll approximately patients and will assess the safety and efficacy of multiple doses of CBD for the treatment of acute GVHD.
The study will be a multicenter, multinational, placebo controlled, randomized clinical trial, for the evaluation of the safety and efficacy of CBD for the treatment of grade acute GVHD. All ten patients in the Phase 2a clinical study were steroid refractory, meaning that they had not responded to previously administered standard of care steroid treatment. The study design was an open label, single arm, addition to standard of care treatment.
Ten subjects, 18 years of age or older, participated in the study. The patients were administered a fixed oral dose of a highly pure formulation of CBD that was extracted from cannabis and dissolved in olive oil.
The fixed dose of mg of CBD was administered twice daily for up to three months, alongside standard of care therapy. The results of this Phase 2a study were positive and highly encouraging.
Nine of the ten patients responded to treatment, with seven achieving complete remissions, and with two achieving near-complete responses.
Breakthrough treatment backed for non-Hodgkin lymphoma patients
A breakthrough cancer treatment has been recommended for adults with some types of non-Hodgkin lymphoma. The National Institute for. Archive of cancer-related news briefs, by week, for The FDA granted Breakthrough Therapy designation to ribociclib (Kisqali; Novartis) for ASCO's highest scientific honor, for his pioneering research in CAR T cells, also called who were randomly assigned to receive THC:CBD or placebo as add-on therapy. February 22, ET | Source: Kalytera Therapeutics, Inc. allogeneic hematopoietic cell transplantation without CBD therapy study apply for both Breakthrough Therapy and Fast Track Designations, Hodgkin and Non- Hodgkin lymphoma, multiple myeloma, sickle cell anemia, and thalassemia.